Diffusion Pharmaceuticals Inc (NASDAQ:DFFN)’s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $0.28 and last traded at $0.30, with a volume of 7634 shares trading hands. The stock had previously closed at $0.29.
DFFN has been the subject of several research analyst reports. ValuEngine upgraded shares of Diffusion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. HC Wainwright reiterated a “buy” rating and set a $1.25 target price on shares of Diffusion Pharmaceuticals in a research note on Monday, August 20th.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last announced its earnings results on Wednesday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.07). On average, analysts forecast that Diffusion Pharmaceuticals Inc will post -0.43 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2018/12/01/diffusion-pharmaceuticals-dffn-sets-new-52-week-low-at-0-28.html.
Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.
Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.